CLOSEOUT LETTER

Biomerieux Inc September 18, 2015

Recipient:: Biomerieux Inc; United States

Issuing Office:: United States


Department of Health and Human Services
	Food and Drug Administration Southwest Region Kansas City District 8050 Marshall Drive Suite 205 Lenexa. Kansas 66214-1524 913-495-5100

September 18, 2015

Jean-Luc Belingard, CEO
BioMerieux SA
Chemin de I'Orme
69280 Marcy I'Etoile, Rhone-Alpes
France

Dear Mr. Belingard:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter [Ref: CMS # 441451]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/S/

Cheryl A. Bigham
KAN-DO District Director

Cc: Antonio M. Santos
      Vice President, Operations
      Biomerieux Inc.
      595 Anglum Rd.
      Hazelwood, MO 63042

Department of Health and Human Services